• Introduction to Cancer Therapy
• 46 min
  1. Development of a cancer drug

  • Prof. Martin Edelman
• Use of Novel "Targeted" Agents in Combination with Classical Cytotoxic Chemotherapy
• 35 min
  2. Small molecule inhibitors of receptor tyrosine kinases

  • Dr. Daniela Krause
• Innovative Strategies of Clinical Drug Development
• 46 min
  3. Phase II trials

  • Dr. Patricia Tang
• 33 min
  4. Surrogate endpoints of efficacy

  • Prof. Maurie Markman
• Biomarkers in Oncology: Rationale Development and Current Use
• 27 min
  5. Biomarkers in oncology: overview

  • Prof. Joe Duffy
• 55 min
  6. Genetic polymorphism of thiopurine methyltransferase and thiopurine therapy: from molecular genetics to clinical medicine

  • Dr. William Evans
• Archived Lectures *These may not cover the latest advances in the field
• 42 min
  7. Emerging trends in phase II trial design

  • Dr. Patricia Tang
• 36 min
  8. EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients

  • Prof. Fred Hirsch
• 36 min
  9. Therapy in cancer 2008: quo vadis?

  • Dr. Jeffrey Clark
• 34 min
  10. Changing paradigms in anticancer drug development: inhibiting angiogenesis in colorectal cancer

  • Prof. David Kerr
• 32 min
  11. Phase III trials

  • Prof. Martin Edelman
• 43 min
  12. Germline pharmacogenomics as a tool to individualize therapy in breast cancer

  • Dr. David Flockhart
• 33 min
  13. Gene profiling in breast cancer

  • Dr. Enrique Espinosa
• 31 min
  14. UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients

  • Prof. Tae Won Kim
• 28 min
  15. Principles of cancer treatment: surgery, radiotherapy, chemotherapy, immunotherapy

  • Dr. Theodore Yaeger
• 25 min
  16. Understanding cancer trends

  • Prof. Michael Thun
• 54 min
  17. Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

  • Dr. Tracey Evans
• 40 min
  18. Phase I study design for non-cytotoxic agents

  • Dr. Wendy Parulekar
• 36 min
  19. Early detection of lung cancer

  • Prof. Stephen Lam
• 60 min
  20. Cytotoxic chemotherapy

  • Dr. Michael Sawyer

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Epidemiology (1)
3. Epidemiology (2)
4. Potential roles of genomics
5. Areas for improvement
6. Classical prognostic factors
7. Example of the adjuvant online software (1)
8. Example of the adjuvant online software (2)
9. Techniques used in translational studies
10. Microarrays
11. Representation of microarrays
12. RT-PCR
13. Example for PCR representation
14. Breast cancer biology
15. Breast cancer development
16. Breast cancer development as seen in microarrays
17. Metastatic potential present in early tumor stages
18. Gene expression phenotypes in ER+ and ER-
19. Grade 1 and grade 3 of tumor differentiation
20. Grade 2 tumors
21. Molecular taxonomy of breast cancer
22. Molecular subtypes and prognosis
23. Well defined molecular subtypes
24. Luminal vs. basal-like tumors (1)
25. Luminal vs. basal-like tumors (2)
26. Correlation of subtypes with prognostic profiles
27. Prediction of response
28. Benefits of predicting response
29. Current predictive markers
30. Single molecular predictors
31. Prediction of response docetaxel - 92 genes
32. Prediction of response docetaxel - 85 genes
33. Prediction of response paclitaxel
34. Prediction of response tamoxifen - 81 genes (1)
35. Prediction of response tamoxifen - 81 genes (2)
36. Subtypes and response to chemotherapy
37. Prognosis
38. Importance pf prognosis
39. Development of gene predictors
40. Amsterdam 70-gene profile (1)
41. Amsterdam 70-gene profile (2)
42. MammaPrint: independent validation
43. Rotterdam 76-gene profile
44. Recurrence score 21 gene profile
45. Recurrence score by group
46. Recurrence score survival
47. Recurrence score as a continuous predictor
48. Recurrence score independent of size/age
49. Development of recurrence score
50. Validation of recurrence score (1)
51. Validation of recurrence score (2)
52. Conditions to use gene profiles
53. EORTC-BIG: MINDACT
54. TAILOR-x
55. Conclusions (1)
56. Conclusions (2)
57. Acknowledgements

Topics Covered

• DNA microarrays and PCR can provide information about the biology of breast cancer, prediction of response and prognosis
• A molecular taxonomy of breast cancer has been proposed based on gene profiling
• Prediction of response is still inaccurate and further studies should be performed
• Several prognostic profiles have proved advantage over classical prognostic factors
• They could be used in the near future to select patients for adjuvant chemotherapy in breast cancer

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on January 6, 2009
• Archived on February 25, 2021

Financial Disclosures

• Dr. Enrique Espinosa has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.